A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure

NCT ID: NCT06635135

Last Updated: 2025-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-19

Study Completion Date

2025-04-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective serotonin reuptake inhibitor \[SSRI\] or serotonin-norepinephrine reuptake inhibitor \[SNRI\]) in preventing return of depression symptoms in participants with major depressive disorder who experience a loss of interest and pleasure and who achieve a stable response after treatment with adjunctive aticaprant.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depressive Disorder, Major Anhedonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aticaprant

Group Type EXPERIMENTAL

Aticaprant

Intervention Type DRUG

Aticaprant will be administered orally.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo will be administered orally.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aticaprant

Aticaprant will be administered orally.

Intervention Type DRUG

Placebo

Placebo will be administered orally.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

JNJ-67953964

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be medically stable based on physical examination (including a brief neurologic examination), medical history, vital signs (including blood pressure), and 12-lead electrocardiogram (ECG) performed at screening and OL baseline
* Be medically stable based on clinical laboratory tests performed at screening
* Meet DSM-5 diagnostic criteria for recurrent or single episode MDD, without psychotic features upon clinical assessment and confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) Axis I Disorders-Clinical Trials version (SCID-CT)
* Have symptoms of anhedonia based on clinical assessment and confirmed by presence of anhedonia (positive response to major depressive episode (MDE) module symptom Item 2) on the SCID-CT at screening

Exclusion Criteria

* Has had no response to 2 or more consecutive antidepressant treatments administered at adequate dose and duration in the current episode of depression including the current selective SSRI/SNRI assessed using the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH ATRQ)
* Has a history or evidence of clinically meaningful noncompliance with current antidepressant therapy
* Has a history of moderate-to-severe substance use disorder including alcohol use disorder according to DSM-5 criteria within 6 months before screening
* Has homicidal ideation/intent, per the investigator's clinical judgment, or has suicidal ideation with some intent to act within 3 months prior to the start of the screening phase
* Has cognitive impairment per investigator judgment that would render the informed consent invalid or limit the ability of the participant to comply with the study requirements
Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Janssen Research & Development, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Janssen Research & Development, LLC Clinical Trial

Role: STUDY_DIRECTOR

Janssen Research & Development, LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Preferred Research Partners

Little Rock, Arkansas, United States

Site Status

Wake Research PRI Encino

Encino, California, United States

Site Status

Wr Pri Llc

Newport Beach, California, United States

Site Status

ATP Clinical Research

Orange, California, United States

Site Status

Myndful Research

Redlands, California, United States

Site Status

Artemis Institute for Clinical Research

San Diego, California, United States

Site Status

UHC Research

Doral, Florida, United States

Site Status

Pharmax Research Clinic Inc

Miami, Florida, United States

Site Status

GTL Medical and Research Group

Miami, Florida, United States

Site Status

International Research Associates, LLC

Miami, Florida, United States

Site Status

Harmony Clinical Research Inc

North Miami Beach, Florida, United States

Site Status

APG Research LLC

Orlando, Florida, United States

Site Status

Interventional Psychiatry of Tampa Bay

Tampa, Florida, United States

Site Status

Synexus Clinical Research US Inc

Atlanta, Georgia, United States

Site Status

Chicago Research Center

Chicago, Illinois, United States

Site Status

Psychiatric Medicine Associates LLC

Skokie, Illinois, United States

Site Status

Continental Clinical Solutions

Towson, Maryland, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

University of Missouri Health Care

Columbia, Missouri, United States

Site Status

IMA Clinical Research PC

Albuquerque, New Mexico, United States

Site Status

Integrative Clinical Trials LLC

Brooklyn, New York, United States

Site Status

Bioscience Research LLC

Mount Kisco, New York, United States

Site Status

Patient Priority Clinical Sites LLC

Cincinnati, Ohio, United States

Site Status

Insight Clinical Trials

Independence, Ohio, United States

Site Status

Laureate Institute for Brain Research

Tulsa, Oklahoma, United States

Site Status

Keystone Clinical Studies LLC

Plymouth Meeting, Pennsylvania, United States

Site Status

Coastal Carolina Research Center

North Charleston, South Carolina, United States

Site Status

InSite Clinical Research LLC

DeSoto, Texas, United States

Site Status

Earle Research

Friendswood, Texas, United States

Site Status

Alpine Research Organization

Clinton, Utah, United States

Site Status

Elligo Integrated Research Sites Integrated Clinical Research LLC Integrated Psych

St. George, Utah, United States

Site Status

Hospital Italiano de Buenos Aires

Buenos Aires, , Argentina

Site Status

Centro Medico Instituto Modelo de Neurologia y Neurorehabilitacion

Córdoba, , Argentina

Site Status

Anima

Alken, , Belgium

Site Status

AZ Sint-Lucas

Assebroek, , Belgium

Site Status

UZ Brussel

Brussels, , Belgium

Site Status

AZ Oudenaarde

Oudenaarde, , Belgium

Site Status

Vitaz

Sint-Niklaas, , Belgium

Site Status

CAEP Centro Avancado De Estudos E Pesquisas

Campinas, , Brazil

Site Status

Centro Integrado Facili

São Bernardo do Campo, , Brazil

Site Status

Mental Health Center - Rousse

Rousse, , Bulgaria

Site Status

Medical Centre Akademika EOOD

Sofia, , Bulgaria

Site Status

DCC 'Sv. Vrach and Sv. Sv. Kuzma and Damyan', OOD

Sofia, , Bulgaria

Site Status

Diagnostic Consulting Center Mladost - M Varna

Varna, , Bulgaria

Site Status

Mental Health Center - Vratsa EOOD

Vratsa, , Bulgaria

Site Status

CHRU Besancon Hopital Jean Minjoz

Besançon, , France

Site Status

Hopital la Colombiere

Montpellier, , France

Site Status

CHU de Nantes hotel Dieu

Nantes, , France

Site Status

CHS du Rouvray

Sotteville-lès-Rouen, , France

Site Status

Hopital Sainte Musse

Toulon, , France

Site Status

Klinische Forschung Berlin-Mitte GmbH

Berlin, , Germany

Site Status

Praxis Dr. med. Kirsten Hahn

Berlin, , Germany

Site Status

Pharmakologisches Studienzentrum Chemnitz GmbH

Chemnitz, , Germany

Site Status

Universitatsklinikum Frankfurt

Frankfurt am Main, , Germany

Site Status

Klinische Forschung Hamburg

Hamburg, , Germany

Site Status

Oberhavel Kliniken GmbH

Hennigsdorf, , Germany

Site Status

Universitaetsklinikum Muenster

Münster, , Germany

Site Status

Boehm Peters Praxis fur Psychiatrie Psychotherapie Neurologie PartGmbB

Rosenheim, , Germany

Site Status

Klinische Forschung Schwerin GmbH

Schwerin, , Germany

Site Status

Eginitio Hospital

Athens, , Greece

Site Status

Attikon University General Hospital of Attica

Athens, , Greece

Site Status

University Hospital of Heraklion

Heraklion, , Greece

Site Status

University General Hospital of Ioannina

Ioannina, , Greece

Site Status

G Papanikolaou Hospital of Thessaloniki

Thessaloniki, , Greece

Site Status

Hospital Aranda de la Parra S A de C V

León, , Mexico

Site Status

Ketamine Mexico S de RL de C V

Mexico City, , Mexico

Site Status

Human Science Research Trials S de RL de CV

México, , Mexico

Site Status

cit NEUROPSIQUE

Monterrey, , Mexico

Site Status

Osrodek Badan Klinicznych CLINSANTE S C Ewa Galczak Nowak Malgorzata Trzaska

Bydgoszcz, , Poland

Site Status

NZOZ Euromedica Grudziadz

Grudziądz, , Poland

Site Status

Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS

Leszno, , Poland

Site Status

Centrum Medyczne Luxmed Sp z o o

Lublin, , Poland

Site Status

Praktyka Lekarska dr n med Malgorzata Wojtanowska Bogacka

Poznan, , Poland

Site Status

Indywidualna Specjalistyczna Praktyka Lekarska Agnieszka Remlinger Molenda

Suchy Las, , Poland

Site Status

Care Access Warszawa

Warsaw, , Poland

Site Status

Szpital Nowowiejski Osrodek Badan Klinicznych

Warsaw, , Poland

Site Status

MTZ Clinical Research Powered by Pratia

Warsaw, , Poland

Site Status

Centrum Zdrowia Mosty

Wroclaw, , Poland

Site Status

Spitalul Clinic de Psihiatrie Prof Dr Alexandru Obregia

Bucharest, , Romania

Site Status

Centrul de Evaluarea si Tratament al Toxicodependentelor pentru Tineri Sf. Stelian

Bucharest, , Romania

Site Status

Centrul Medical Melchisedec

Craiova, , Romania

Site Status

Spitalul Clinic de Neuropsihiatrie

Craiova, , Romania

Site Status

CMI Dr. Sarpe Marcel-Claudiu

Focşani, , Romania

Site Status

Spitalul De Psihiatrie Elisabeta Doamna Galaţi

Galați, , Romania

Site Status

Spitalul Clinic De Psihiatrie Doctor Gheorghe Preda

Sibiu, , Romania

Site Status

Hosp. Univ. de Basurto

Bilbao, , Spain

Site Status

Hosp Reina Sofia

Córdoba, , Spain

Site Status

Hosp. Univ. Virgen de Las Nieves

Granada, , Spain

Site Status

Hosp. Univ. La Paz

Madrid, , Spain

Site Status

Hosp Virgen de La Victoria

Málaga, , Spain

Site Status

Hosp. Univ. Son Espases

Palma, , Spain

Site Status

Clinica Univ. de Navarra

Pamplona, , Spain

Site Status

Hosp. El Bierzo

Ponferrada, , Spain

Site Status

Hosp. Royo Villanova

Zaragoza, , Spain

Site Status

Erenkoy Mental Health Hospital

Istanbul, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Belgium Brazil Bulgaria France Germany Greece Mexico Poland Romania Spain Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

67953964MDD3005

Identifier Type: OTHER

Identifier Source: secondary_id

2024-511057-22-00

Identifier Type: REGISTRY

Identifier Source: secondary_id

67953964MDD3005

Identifier Type: -

Identifier Source: org_study_id